Nadja Kopp

2.7k total citations
21 papers, 643 citations indexed

About

Nadja Kopp is a scholar working on Genetics, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Nadja Kopp has authored 21 papers receiving a total of 643 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 8 papers in Molecular Biology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Nadja Kopp's work include Lymphoma Diagnosis and Treatment (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and CAR-T cell therapy research (4 papers). Nadja Kopp is often cited by papers focused on Lymphoma Diagnosis and Treatment (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and CAR-T cell therapy research (4 papers). Nadja Kopp collaborates with scholars based in United States, Switzerland and Germany. Nadja Kopp's co-authors include David M. Weinstock, Liat Bird, Scott J. Rodig, Ernst Leumann, Andrew L. Kung, Jun Qi, Ronald M. Paranal, Teresa V. Bowman, Christopher J. Ott and James E. Bradner and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Nadja Kopp

20 papers receiving 636 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nadja Kopp United States 9 388 180 163 160 90 21 643
Hiro Tatetsu Japan 15 356 0.9× 127 0.7× 84 0.5× 125 0.8× 123 1.4× 35 600
Shuchi Agrawal India 11 536 1.4× 348 1.9× 121 0.7× 78 0.5× 79 0.9× 21 775
Christiane Mounier France 8 212 0.5× 139 0.8× 178 1.1× 158 1.0× 78 0.9× 14 464
Anna Ferrari Italy 12 272 0.7× 129 0.7× 117 0.7× 55 0.3× 74 0.8× 48 511
Sharmila Mallya United States 12 495 1.3× 138 0.8× 88 0.5× 53 0.3× 108 1.2× 20 656
Olga Sala‐Torra United States 12 233 0.6× 378 2.1× 160 1.0× 64 0.4× 153 1.7× 31 707
Jason E. Farrar United States 15 661 1.7× 204 1.1× 131 0.8× 31 0.2× 84 0.9× 61 914
James M. Bogenberger United States 14 405 1.0× 202 1.1× 181 1.1× 40 0.3× 67 0.7× 26 573
Soumen Chakraborty India 13 434 1.1× 197 1.1× 80 0.5× 60 0.4× 60 0.7× 27 635
T Murate Japan 11 220 0.6× 86 0.5× 203 1.2× 93 0.6× 99 1.1× 15 468

Countries citing papers authored by Nadja Kopp

Since Specialization
Citations

This map shows the geographic impact of Nadja Kopp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nadja Kopp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nadja Kopp more than expected).

Fields of papers citing papers by Nadja Kopp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nadja Kopp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nadja Kopp. The network helps show where Nadja Kopp may publish in the future.

Co-authorship network of co-authors of Nadja Kopp

This figure shows the co-authorship network connecting the top 25 collaborators of Nadja Kopp. A scholar is included among the top collaborators of Nadja Kopp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nadja Kopp. Nadja Kopp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jacobson, Caron A., Nadja Kopp, Jacob V. Layer, et al.. (2016). HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma. Blood. 128(21). 2517–2526. 30 indexed citations
2.
Melchardt, Thomas, Clemens Hufnagl, David M. Weinstock, et al.. (2016). Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones. Oncotarget. 7(32). 51494–51502. 29 indexed citations
3.
Morgan, Elizabeth A., Tamiwe Tomoka, Nadja Kopp, et al.. (2016). Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. Blood Advances. 1(1). 84–92. 8 indexed citations
4.
Townsend, Elizabeth C., Tiffany DeSouza, Mark A. Murakami, et al.. (2015). The MDM2 Inhibitor NVP-CGM097 Is Highly Active in a Randomized Preclinical Trial of B-Cell Acute Lymphoblastic Leukemia Patient Derived Xenografts. Blood. 126(23). 797–797. 8 indexed citations
5.
Li, Loretta S., Shuo-Chieh Wu, Nadja Kopp, et al.. (2014). Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs). Blood. 124(21). 3713–3713. 1 indexed citations
6.
Kopp, Nadja, Sarah Haebe, Diederik van Bodegom, et al.. (2014). Newer-Generation HSP90 Inhibitors Can Overcome Ibrutinib Resistance and Suppress Proliferation in Human Mantle Cell Lymphoma in Vitro and in Vivo. Blood. 124(21). 1686–1686. 4 indexed citations
7.
Kim, Sunhee S., Kristen E. Stevenson, Akinori Yoda, et al.. (2013). Loss-Of-Function Mutations In The Splicing Factor ZRSR2 Are Common In Blastic Plasmacytoid Dendritic Cell Neoplasm and Have Male Predominance. Blood. 122(21). 741–741. 15 indexed citations
8.
Yoda, Akinori, Guillaume Adelmant, Nobuaki Shindoh, et al.. (2013). Abstract PR07: Novel oncogenic mutations in the beta subunit of heteromeric G-proteins identified by functional cDNA library screening.. Molecular Cancer Therapeutics. 12(11_Supplement). PR07–PR07. 1 indexed citations
9.
Dutta, Chaitali, Tovah A. Day, Nadja Kopp, et al.. (2012). BCL2 Suppresses PARP1 Function and Nonapoptotic Cell Death. Cancer Research. 72(16). 4193–4203. 45 indexed citations
10.
Shindoh, Nobuaki, Akinori Yoda, Yuka Yoda, et al.. (2012). Next-Generation cDNA Screening for Oncogene and Resistance Phenotypes. PLoS ONE. 7(11). e49201–e49201. 4 indexed citations
11.
Ott, Christopher J., Nadja Kopp, Liat Bird, et al.. (2012). BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 120(14). 2843–2852. 294 indexed citations
12.
Kopp, Nadja, Christopher J. Ott, Liat Bird, et al.. (2012). BET Bromodomain Inhibition Targets Both c-Myc and IL7R in Acute Lymphoblastic Leukemia. Blood. 120(21). 672–672.
13.
Bodegom, Diederik van, Jun Zhong, Nadja Kopp, et al.. (2012). Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2. Blood. 120(14). 2853–2863. 34 indexed citations
14.
Kopp, Nadja, Liat Bird, Ronald M. Paranal, et al.. (2012). 539 BET Bromodomain Inhibition Targets Both c-Myc and IL7R in Acute Lymphoblastic Leukemia. European Journal of Cancer. 48. 166–166. 1 indexed citations
15.
Weigert, Oliver, Nadja Kopp, Andrew A. Lane, et al.. (2011). Molecular Ontogeny of Donor-Derived Follicular Lymphomas Occurring after Hematopoietic Cell Transplantation. Cancer Discovery. 2(1). 47–55. 64 indexed citations
16.
Weigert, Oliver, Andrew A. Lane, Liat Bird, et al.. (2011). Genetic Resistance to JAK2 Enzymatic Inhibitors Is Overcome by HSP90 Inhibition. Blood. 118(21). 62–62. 4 indexed citations
17.
18.
Besançon, Roger, Philippe Latour, P. Petiot, et al.. (1999). Alternative exon 3 splicing of the human major protein zero gene in white blood cells and peripheral nerve tissue. FEBS Letters. 457(3). 339–342. 7 indexed citations
19.
Kopp, Nadja & Ernst Leumann. (1995). Changing pattern of primary hyperoxaluria in Switzerland. Nephrology Dialysis Transplantation. 10(12). 2224–2227. 65 indexed citations
20.
Chazot, G, et al.. (1979). [Adrenomyeloneuropathy: an adult form of adrenoleukodystrophy spastic paraparesis, and chronic adrenal insufficiency (concerning 3 cases) (author's transl)].. PubMed. 135(3). 211–20. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiro Tatetsu Breakdown of academic impact, for papers by Shuchi Agrawal Breakdown of academic impact, for papers by Christiane Mounier Breakdown of academic impact, for papers by Anna Ferrari Breakdown of academic impact, for papers by Sharmila Mallya Breakdown of academic impact, for papers by Olga Sala‐Torra Breakdown of academic impact, for papers by Jason E. Farrar Breakdown of academic impact, for papers by James M. Bogenberger Breakdown of academic impact, for papers by Soumen Chakraborty Breakdown of academic impact, for papers by T Murate
Rankless by CCL
2026